CREBBP and colorectal carcinoma: Our finding that the CBP/p300 inhibitor CPI‐1612 suppresses C‐terminal acetylation of p53 in irinotecan plus entinostat‐treated CRC cells and consequently apoptosis supports our model of a proapoptotic switch that depends on C‐terminal acetylation of p53.